title: Inhibitory effect of fluvastatin on ileal ulcer formation in rats induced by nonsteroidal antiinflammatory drug.
abstract: OBJECTIVE
  Nonsteroidal anti-inflammatory drugs (NSAIDs) cause gastrointestinal damage as one of their side effects in humans and experimental animals. Lipid peroxidation plays an important role in NSAID-induced ulceration. The aim of this study was to investigate the inhibitory effect of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors on the ulceration in small intestines of rats.
  
  
  METHODS
  The effects of three HMG-CoA reductase inhibitors, fluvastatin, pravastatin and atorvastatin on ileal ulcer formation in 5-bromo-2-(4-fluorophenyl)-3-(4- methylsulfonylphenyl) thiophene (BFMeT)-treated rats were examined. Antioxidative activity of the inhibitors was measured by a redox-linked colorimetric method.
  
  
  RESULTS
  Fluvastatin, which was reported to have antioxidative activity, repressed the ileal ulcer formation in rats treated with BFMeT an NSAIDs. However, the other HMG-CoA reductase inhibitors (pravastatin and atorvastatin) did not repress the ileal ulcer formation. Among these HMG-CoA reductase inhibitors, fluvastatin showed a significantly stronger reducing power than the others (pravastatin, atorvastatin).
  
  
  CONCLUSIONS
  Fluvastatin having the antioxidaitive activity suppresses ulcer formation in rats induced by NSAIDs.
authors.affiliation: Department of Molecular Bacteriology, Graduate School of Medicine, The University of Tokushima, Tokushima 770-8503, Japan.
authors.forename: Mari
authors.initials: M
authors.lastname: Hagiwara
authors.forename: Keiko
authors.initials: K
authors.lastname: Kataoka
authors.forename: Hideki
authors.initials: H
authors.lastname: Arimochi
authors.forename: Tomomi
authors.initials: T
authors.lastname: Kuwahara
authors.forename: Haruyuki
authors.initials: H
authors.lastname: Nakayama
authors.forename: Yoshinari
authors.initials: Y
authors.lastname: Ohnishi
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000975:Antioxidants / Q000494:pharmacology; D000069059:Atorvastatin; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology*; D000077340:Fluvastatin; D006538:Heptanoic Acids / Q000494:pharmacology; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D007077:Ileal Diseases / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D007082:Ileum / Q000473:pathology; D007211:Indoles / Q000494:pharmacology*; D008297:Male; D017035:Pravastatin / Q000494:pharmacology; D011758:Pyrroles / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D014456:Ulcer / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000975:Antioxidants; D005229:Fatty Acids, Monounsaturated; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D007211:Indoles; D011758:Pyrroles; D000077340:Fluvastatin; D000069059:Atorvastatin; D017035:Pravastatin
references.citation: Rheumatol Int. 1982;2(1):1-10
references.pmid: 7178760
references.citation: N Engl J Med. 1992 Sep 10;327(11):749-54
references.pmid: 1501650
references.citation: Biochem Pharmacol. 1999 Dec 15;58(12):1975-80
references.pmid: 10591153
references.citation: J Pharmacol Exp Ther. 1990 Jul;254(1):180-7
references.pmid: 2366180
references.citation: Microbiol Immunol. 1998;42(11):745-53
references.pmid: 9886147
references.citation: Scand J Gastroenterol Suppl. 1989;163:9-16
references.pmid: 2683030
references.citation: Am J Physiol. 1990 Sep;259(3 Pt 1):G462-7
references.pmid: 2169206
references.citation: Am J Dig Dis. 1974 May;19(5):405-10
references.pmid: 4825946
references.citation: Analyst. 1989 May;114(5):631-3
references.pmid: 2757233
references.citation: BMJ. 1988 Aug 13;297(6646):488-9
references.pmid: 3139171
references.citation: Med Sci Monit. 2001 Jul-Aug;7(4):592-9
references.pmid: 11433182
references.citation: Biol Pharm Bull. 2000 Jul;23(7):873-8
references.pmid: 10919369
references.citation: Gastroenterology. 1989 Feb;96(2 Pt 2 Suppl):640-6
references.pmid: 2642450
references.citation: Dig Dis Sci. 1979 Jan;24(1):53-64
references.pmid: 371938
references.citation: Dig Dis Sci. 1998 Sep;43(9 Suppl):30S-34S
references.pmid: 9753223
references.citation: Microbiol Immunol. 1998;42(5):347-55
references.pmid: 9654366
references.citation: Eur J Pharmacol. 1998 Nov 13;361(1):143-9
references.pmid: 9851551
references.citation: Chem Pharm Bull (Tokyo). 1999 Oct;47(10):1477-80
references.pmid: 10553644
references.citation: Br Med J (Clin Res Ed). 1985 Feb 2;290(6465):347-9
references.pmid: 3917814
references.citation: Chem Pharm Bull (Tokyo). 1999 Jul;47(7):1010-2
references.pmid: 10434403
references.citation: Scand J Gastroenterol. 1995 Apr;30(4):289-99
references.pmid: 7610343
references.citation: N Engl J Med. 1999 Jan 14;340(2):115-26
references.pmid: 9887164
references.citation: Methods Find Exp Clin Pharmacol. 1998 Dec;20(10):849-54
references.pmid: 10091221
references.citation: Anal Biochem. 1996 Jul 15;239(1):70-6
references.pmid: 8660627
references.citation: Gastroenterology. 1987 Sep;93(3):480-9
references.pmid: 3609658
references.citation: Microbiol Immunol. 1996;40(8):553-60
references.pmid: 8887349
references.citation: Food Chem Toxicol. 2000 Jan;38(1):7-13
references.pmid: 10685009
references.citation: Gut. 1993 Jun;34(6):732-7
references.pmid: 8314503
references.citation: N Engl J Med. 1997 Apr 3;336(14):973-9
references.pmid: 9077376
references.citation: Gastroenterology. 1993 Jun;104(6):1832-47
references.pmid: 8500743
references.citation: Arch Toxicol. 1990;64(3):210-7
references.pmid: 2115324